Science advancesMar 18, 2026

Using a self-turning-off gene editing tool at different ages helps improve Huntington's disease symptoms over time in mice

CRISPR Gene Editing Weekly Brief ↗PubMed ↗DOI ↗

Updated Jun 27, 2026

Abstract

Essence

Self-inactivating AAV-CRISPR reduced mutant huntingtin and improved Huntington's-like deficits in BAC226Q mice.

Evidence

This was a preclinical gene-editing study in BAC226Q mouse brains, where conventional and self-inactivating SaCas9 systems lowered mHTT protein by 60 to 90%, reduced aggregation by 90%, and improved pathology, motor signs, weight, and lifespan across treatment ages.

Caveat

This is proof-of-concept mouse data, so human delivery, safety, and clinical efficacy were not tested.

Simplified

Huntington's disease (HD) is a monogenic autosomal dominant neurodegenerative disorder caused by a CAG repeat expansion in exon 1 of thegene, yielding a gain-of-toxic-function mutant Huntingtin protein (mHTT). CRISPR-Cas9 is a potentially powerful therapeutic strategy for HD by eliminating mutant(m) gene. We developed a specific SaCas9 guide RNA to target human mand a self-inactivating gene editing system that abolishes SaCas9 after a short transient expression for high gene editing efficiency and maximal safety to prevent off-target effects. Both conventional and the self-inactivating gene editing systems successfully eliminated mgene, 60 to 90% mHTT protein and 90% of mHTT aggregation in BAC226Q mouse brains, which resulted in significant long-term rescue of neuropathology, motor deficits, weight loss, and shortened life span. These beneficial effects were observed when gene editing was applied before, at, and well after the onset of pathological and behavioral abnormalities. These proof-of-concept data demonstrate that gene editing can be a highly effective therapeutic approach for HD. HTT HTT HTT HTT HTT